<p>根据 Nordea Investment Management AB 最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第二季度将其在雅培（NYSE:ABT - 免费报告）的持股比例提高了 6.6%。该基金在此期间额外购买了 19,282 股后，持有 310,456 股该医疗产品制造商的股票。Nordea Investment Management AB 在雅培的持股在最近一个季度末价值为 41,921,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在雅培的持股提高了 0.7%。先锋集团目前拥有 169,823,136 股该医疗产品制造商的股票，价值 22,527,039,000 美元，此前在上个季度又购买了 1,177,739 股。威灵顿管理集团（Wellington Management Group LLP）在第一季度将其在雅培的持股提高了 12.8%。威灵顿管理集团目前拥有 29,763,415 股该医疗产品制造商的股票，价值 3,948,117,000 美元，此前在上个季度又购买了 3,371,113 股。高盛集团（Goldman Sachs Group Inc.）在第一季度将其在雅培的持股提高了 29.2%。高盛集团目前拥有 15,985,797 股该医疗产品制造商的股票，价值 2,120,516,000 美元，此前在上个季度又购买了 3,616,471 股。马萨诸塞金融服务公司（Massachusetts Financial Services Co. MA）在第一季度将其在雅培的持股提高了 12.8%。马萨诸塞金融服务公司目前拥有 14,451,305 股该医疗产品制造商的股票，价值 1,916,966,000 美元，此前在上个季度又购买了 1,639,954 股。最后，查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在雅培的持股提高了 1.3%。查尔斯·施瓦布投资管理公司目前拥有 13,108,416 股该医疗产品制造商的股票，价值 1,738,831,000 美元，此前在上个季度又购买了 168,095 股。75.18% 的股票目前由机构投资者持有。</p>
<h2>内部活动</h2>
<p>在其他消息中，首席财务官 Philip P. Boudreau 于 8 月 8 日星期五出售了 5,550 股公司的股票。该股票以 134.55 美元的平均价格出售，总交易额为 746,752.50 美元。出售完成后，首席财务官直接持有 51,003 股公司的股票，价值为 6,862,453.65 美元。这笔交易代表其持股减少了 9.81%。该出售在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。0.46% 的股票目前由公司内部人士持有。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>为什么雅培是 2025 年第二季度的买入：增长与收益</li>
</ul>
<p>雅培成为多份研究分析师报告的主题。摩根士丹利（Morgan Stanley）在 7 月 15 日的报告中将雅培的目标价格从 127.00 美元提高至 137.00 美元，并给予该股票 “持平” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对雅培股票的 “买入（b）” 评级。桑福德·伯恩斯坦（Sanford C. Bernstein）在周四的报告中将雅培的目标价格从 145.00 美元提高至 150.00 美元，并给予该股票 “跑赢大盘” 评级。威廉·布莱尔（William Blair）在 7 月 17 日的报告中将雅培升级为 “强力买入” 评级。最后，富国银行（Wells Fargo &amp; Company）在周四的报告中将雅培的目标价格从 142.00 美元提高至 146.00 美元，并给予该股票 “超配” 评级。两位股票研究分析师对该股票给予了 “强力买入” 评级，十六位分析师给予了 “买入” 评级，四位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 147.61 美元。</p>
<p><strong>查看我们对雅培的最新分析</strong></p>
<h2>雅培股票表现</h2>
<ul>
<li>如果你想购买 AbbVie 但没有，现在仍然有机会购买</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）周五开盘价为 128.69 美元。该公司的流动比率为 1.82，速动比率为 1.30，债务与股本比率为 0.25。该股票的 50 日简单移动平均线为 132.38 美元，200 日简单移动平均线为 131.54 美元。雅培的 1 年最低价为 110.86 美元，1 年最高价为 141.23 美元。该股票的市值为 2239.8 亿美元，市盈率为 16.13，市盈增长比率为 2.44，贝塔值为 0.69。</p>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 10 月 15 日发布了季度财报。该医疗产品制造商报告本季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.78%，净利润率为 31.88%。该公司本季度的收入为 113.7 亿美元，而分析师预期为 114 亿美元。去年同期，该公司的每股收益为 1.21 美元。该公司的收入同比增长了 6.9%。雅培已将其 2025 财年的指导目标设定为每股收益 5.120-5.180 美元。整体来看，分析师预测雅培在当前财年将发布每股收益 5.14 美元。</p>
<h2>雅培股息公告</h2>
<p>该公司还最近宣布了一项季度股息，将于 11 月 17 日星期一支付。10 月 15 日星期三的股东将获得每股 0.59 美元的股息。该股息的除息日期为 10 月 15 日星期三。这代表着每年 2.36 美元的股息和 1.8% 的股息收益率。雅培的股息支付比率（DPR）目前为 29.57%。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培（Abbott Laboratories）及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个业务部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不足、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>强生的并购策略才是投资者真正关注的故事</li>
<li>三只天然气股票提供优厚的股息收益</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌吗？</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>对美元的对冲基金态度转变——这三只股票的买入信号？</li>
</ul>
<p><strong>想看看其他对雅培持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>Nordea Investment Management AB 在第二季度将其在雅培（NYSE:ABT）的持股增加了 6.6%，增持了 19,282 股，总持股达到 310,456 股，价值约为 4190 万美元。其他机构投资者，包括先锋集团和高盛，也增加了他们的持股。分析师对雅培的股票给予了积极的评级，普遍目标价为 147.61 美元。该股票开盘价为 128.69 美元，市值为 2239.8 亿美元，市盈率为 16.13</p>

<p>Nordea Investment Management AB boosted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 310,456 shares of the healthcare product maker's stock after acquiring an additional 19,282 shares during the period. Nordea Investment Management AB's holdings in Abbott Laboratories were worth $41,921,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Nordea Investment Management AB 最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第二季度将其在雅培（NYSE:ABT - 免费报告）的持股比例提高了 6.6%。该基金在此期间额外购买了 19,282 股后，持有 310,456 股该医疗产品制造商的股票。Nordea Investment Management AB 在雅培的持股在最近一个季度末价值为 41,921,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 169,823,136 shares of the healthcare product maker's stock worth $22,527,039,000 after buying an additional 1,177,739 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Abbott Laboratories by 12.8% during the 1st quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker's stock worth $3,948,117,000 after buying an additional 3,371,113 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Abbott Laboratories by 29.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker's stock worth $2,120,516,000 after buying an additional 3,616,471 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Abbott Laboratories by 12.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 14,451,305 shares of the healthcare product maker's stock worth $1,916,966,000 after buying an additional 1,639,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Abbott Laboratories by 1.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,108,416 shares of the healthcare product maker's stock worth $1,738,831,000 after buying an additional 168,095 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在雅培的持股提高了 0.7%。先锋集团目前拥有 169,823,136 股该医疗产品制造商的股票，价值 22,527,039,000 美元，此前在上个季度又购买了 1,177,739 股。威灵顿管理集团（Wellington Management Group LLP）在第一季度将其在雅培的持股提高了 12.8%。威灵顿管理集团目前拥有 29,763,415 股该医疗产品制造商的股票，价值 3,948,117,000 美元，此前在上个季度又购买了 3,371,113 股。高盛集团（Goldman Sachs Group Inc.）在第一季度将其在雅培的持股提高了 29.2%。高盛集团目前拥有 15,985,797 股该医疗产品制造商的股票，价值 2,120,516,000 美元，此前在上个季度又购买了 3,616,471 股。马萨诸塞金融服务公司（Massachusetts Financial Services Co. MA）在第一季度将其在雅培的持股提高了 12.8%。马萨诸塞金融服务公司目前拥有 14,451,305 股该医疗产品制造商的股票，价值 1,916,966,000 美元，此前在上个季度又购买了 1,639,954 股。最后，查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在雅培的持股提高了 1.3%。查尔斯·施瓦布投资管理公司目前拥有 13,108,416 股该医疗产品制造商的股票，价值 1,738,831,000 美元，此前在上个季度又购买了 168,095 股。75.18% 的股票目前由机构投资者持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Philip P. Boudreau 于 8 月 8 日星期五出售了 5,550 股公司的股票。该股票以 134.55 美元的平均价格出售，总交易额为 746,752.50 美元。出售完成后，首席财务官直接持有 51,003 股公司的股票，价值为 6,862,453.65 美元。这笔交易代表其持股减少了 9.81%。该出售在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。0.46% 的股票目前由公司内部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么雅培是 2025 年第二季度的买入：增长与收益</li>
</ul>
</div><p>ABT has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an &#34;equal weight&#34; rating in a report on Tuesday, July 15th. Weiss Ratings reiterated a &#34;buy (b)&#34; rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Sanford C. Bernstein increased their target price on Abbott Laboratories from $145.00 to $150.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. William Blair upgraded Abbott Laboratories to a &#34;strong-buy&#34; rating in a report on Thursday, July 17th. Finally, Wells Fargo &amp; Company increased their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $147.61.</p>
<div class="lb-trans"><p>雅培成为多份研究分析师报告的主题。摩根士丹利（Morgan Stanley）在 7 月 15 日的报告中将雅培的目标价格从 127.00 美元提高至 137.00 美元，并给予该股票 “持平” 评级。Weiss Ratings 在 10 月 8 日的报告中重申了对雅培股票的 “买入（b）” 评级。桑福德·伯恩斯坦（Sanford C. Bernstein）在周四的报告中将雅培的目标价格从 145.00 美元提高至 150.00 美元，并给予该股票 “跑赢大盘” 评级。威廉·布莱尔（William Blair）在 7 月 17 日的报告中将雅培升级为 “强力买入” 评级。最后，富国银行（Wells Fargo &amp; Company）在周四的报告中将雅培的目标价格从 142.00 美元提高至 146.00 美元，并给予该股票 “超配” 评级。两位股票研究分析师对该股票给予了 “强力买入” 评级，十六位分析师给予了 “买入” 评级，四位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价格为 147.61 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我们对雅培的最新分析</strong></p>
</div><h2>Abbott Laboratories Price Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想购买 AbbVie 但没有，现在仍然有机会购买</li>
</ul>
</div><p>Shares of NYSE:ABT opened at $128.69 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock's fifty day simple moving average is $132.38 and its two-hundred day simple moving average is $131.54. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The stock has a market cap of $223.98 billion, a PE ratio of 16.13, a price-to-earnings-growth ratio of 2.44 and a beta of 0.69.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）周五开盘价为 128.69 美元。该公司的流动比率为 1.82，速动比率为 1.30，债务与股本比率为 0.25。该股票的 50 日简单移动平均线为 132.38 美元，200 日简单移动平均线为 131.54 美元。雅培的 1 年最低价为 110.86 美元，1 年最高价为 141.23 美元。该股票的市值为 2239.8 亿美元，市盈率为 16.13，市盈增长比率为 2.44，贝塔值为 0.69。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts' expectations of $11.40 billion. During the same period last year, the business earned $1.21 EPS. The business's revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 10 月 15 日发布了季度财报。该医疗产品制造商报告本季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.78%，净利润率为 31.88%。该公司本季度的收入为 113.7 亿美元，而分析师预期为 114 亿美元。去年同期，该公司的每股收益为 1.21 美元。该公司的收入同比增长了 6.9%。雅培已将其 2025 财年的指导目标设定为每股收益 5.120-5.180 美元。整体来看，分析师预测雅培在当前财年将发布每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培股息公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 11 月 17 日星期一支付。10 月 15 日星期三的股东将获得每股 0.59 美元的股息。该股息的除息日期为 10 月 15 日星期三。这代表着每年 2.36 美元的股息和 1.8% 的股息收益率。雅培的股息支付比率（DPR）目前为 29.57%。</p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories）及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个业务部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不足、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>强生的并购策略才是投资者真正关注的故事</li>
<li>三只天然气股票提供优厚的股息收益</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌吗？</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>对美元的对冲基金态度转变——这三只股票的买入信号？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对雅培持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nordea Investment Management AB 购入了雅培公司 19,282 股股票